Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 139, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111688
Keywords
Schisandra chinensis polysaccharides; Angiotensin II; Transverse aortic constriction; Oxidative stress; Trx-1; TXNIP
Funding
- Science and Technology Bureau of Jiaxing City, Zhejiang, China [2021AY30012, 2019AY32019, 2020AD30114, 2018AD32049, 2020AD30119]
- Second Affiliated Hospital of Jiaxing University Hospital Level Cultivation Project [Jiaxing China] [Y2019-101]
Ask authors/readers for more resources
The study demonstrated that the antioxidative effects of SCP in attenuating oxidative stress were mediated through the regulation of the TXNIP/Trx-1 pathway, potentially making TXNIP a therapeutic target for treating cardiac hypertrophy.
Cardiac hypertrophy is a current, major, global health challenge. Oxidative stress is an important mechanism that contributes to the pathogenesis of cardiac hypertrophy. Schisandra chinensis polysaccharides (SCP), the primary active constituent in Schisandra chinensis, have antioxidative properties. Here, we investigated the role played by SCP in a cardiac hypertrophy model mouse induced by transverse aortic constriction (TAC). We found that SCP treatment improved cardiac function by inhibiting myocardial hypertrophy and oxidative stress. Angiotensin II was used to induce cardiomyocyte hypertrophy and oxidative stress in vitro. We discovered that the antioxidant effects of SCP were mediated through the regulation of the thioredoxin-interacting protein (TXNIP)/Thioredoxin1 (Trx-1) pathway. Using molecular docking, we found that SCP binds to Arg207, Ser169, Lys166, Lys286 and Ser285 in TXNIP through hydrogen bonds. TXNIP is an endogenous inhibitor of Trx-1, and the binding SCP with TXNIP may restrict or interfere with the binding between TXNIP and Trx-1, resulting in Trx-1 activation. In conclusion, our findings demonstrated that the potential use of SCP as a TXNIP inhibitor to attenuate oxidative stress, suggesting that TXNIP might represent a potential therapeutic target for the treatment of cardiac hypertrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available